We asked 443 Midwest adults what would win them over to ketamine-type therapy, and their own doctor dwarfed every other answer at 74 percent. Relatives and friends drew 18 percent, someone they follow online 4, ads 2, and podcast hosts 1. These are final figures.
If you are trying to get care for someone else, that ranking is less a verdict on you than a map of the system. The clinician is the hinge, so it helps to understand in plain terms how the machinery behind that hinge works: what the diagnostic language means, how a referral travels, what gets confused with what, and where coverage decides things.
The phrase that unlocks the conversation
Most of what follows depends on one clinical term, treatment-resistant depression. No single universal definition exists, and clinicians and insurers draw the line in slightly different places. In practice it usually describes depression that stayed stubborn through at least two separate antidepressant trials, each at a reasonable dose for a reasonable time, within the current episode. The qualifiers do the heavy lifting: a drug stopped after eight days of nausea generally does not count, and neither does a prescription never filled.
That is why a written medication history beats any argument you could make. The clinician is asking whether the record shows genuine, adequate trials, and "a few things that did not help" cannot answer that. A list of names, dates, doses, and outcomes can.
Two different things share one word
Esketamine, sold under the name Spravato, is the version with FDA approval for treatment-resistant depression. The nasal spray never goes home with the patient: they take it themselves under direct supervision inside a certified setting enrolled in a restricted federal safety program, then wait through a monitoring period before leaving. It carries specific warnings and a defined protocol, which is why the certified setting exists. For a concrete example of that protocol, Brain Recovery Centers describes how its Spravato treatment is structured.
At-home ketamine, usually a compounded lozenge or troche sent by a telehealth prescriber, is a different category: an older anesthetic used off label for mood. Off-label prescribing is lawful and widespread, but it is not an FDA approval for this use, and it carries none of the same supervision, setting, or monitoring requirements. Treat the two as separate subjects, and notice when a website or forum post slides between them without saying which it means.
How a referral actually moves
- A primary care visit. The history comes up, the poor response to standard treatment is documented, and the clinician decides whether a psychiatric referral is warranted.
- A psychiatric evaluation. Treatment resistance is assessed rather than assumed, other explanations are ruled in or out, current medications are reviewed, and next-step options are weighed. Esketamine is one possibility among several, not the default.
- A referral to a certified site, if that provider thinks it fits. Not every psychiatric practice is certified, so this often means a handoff elsewhere.
- Intake and benefits checks there. Records are requested, eligibility is reviewed, and prior authorization often goes to the insurer before anything is scheduled.
- Scheduling, built around the supervision and monitoring period, which is why visits run long and rides must be arranged ahead.
Two things surprise families. The path is slower than expected, mostly because records and authorizations move at their own pace, and it has several handoffs, which is where cases get lost. A polite call to confirm records arrived is not nagging; it is the most useful thing a caregiver can do in this stretch. Also, unless your loved one signs a release naming you, the clinic cannot legally discuss their care with you, so handle that at the first visit.
What a certified setting involves
Broadly, and without describing any one clinic's protocol, the dose is taken on site, the patient stays for monitoring, vital signs are checked, and driving is off for the rest of the day, so someone must bring them home. Sessions follow a schedule through an initial phase, so plan the time around work and childcare before starting.
Where insurance enters, and how much it decides
Ask people what matters in choosing a provider for this and coverage dominates, with 85 percent of respondents ranking it first or second; nearness came second at 43 percent, then FDA approval at 27 and speed of results at 24.
A separate question asked how heavily insurance would bear on trying the treatment at all. For 22 percent it would decide the matter, and 43 percent more rated it a big factor, 65 percent combined. FDA approval ran close behind: 19 percent deciding, 40 percent big, 59 percent together.
The mechanics behind those numbers matter. Because esketamine is given in a certified setting rather than picked up at a pharmacy, it is usually billed differently from a prescription, and coverage often hinges on prior authorization. The insurer typically wants records of the failed medication trials first, the same paperwork that opened the clinical conversation. At-home ketamine, off label and often compounded, generally sits outside that structure.
Questions for intake staff, in order: is this esketamine in a certified setting or something else, do you bill my plan or is it self-pay, is prior authorization needed and who submits it, what is the expected cost per session, and how many sessions are in the first phase?
What this article cannot do
This explains how a care pathway is structured, drawing on a survey about how people choose care. It is not medical advice or a treatment recommendation, and it makes no claim about outcomes. Whether esketamine or anything else suits the person you are helping depends on their diagnosis, history, medications, and risks, a judgment for a clinician who knows all of it.
Some of this reading happens during hard weeks. If the person you are helping is in danger, or you are at the end of your own rope, dial or text 988; Lifeline counselors answer nationwide around the clock, every day of the year, and you do not have to be the one in crisis to reach out.
Methodology
This publisher commissioned and paid for survey 395586438, which Pollfish fielded on its consumer panel before closing it on June 23, 2026. Respondents, n=443, ranged from 18 to 64 in age and came from ten Midwest states. Where respondents could choose more than one answer, totals exceed 100. Every figure reflects the completed final panel validation.